Veracyte

Yahoo Finance • 8 hours ago

Cathie Wood's ARK boosts Palantir, Tesla, Roninhood bets; cuts semiconductor exposure

Joe Raedle Cathie Wood’s ARK Invest funds executed a broad rotation across technology, healthcare, and industrial names during the last week while markets remained volatile over broader geopolitical tensions between the U.S. and Iran. Bu... Full story

Yahoo Finance • 12 days ago

Cathie Wood Just Snapped Up This Nvidia Cloud Play — Here's Everything Else Ark Traded Monday

On Monday, Ark Invest, led by Cathie Wood, made significant trades, notably acquiring shares of CoreWeave Inc. This purchase aligns with Ark’s strategy of investing in innovative technology companies. CoreWeave, a cloud platform built on N... Full story

Yahoo Finance • 2 months ago

What Veracyte (VCYT)'s UBS Rating Reaffirmation and 2026 Outlook Means For Shareholders

UBS recently reaffirmed its Buy rating on Veracyte after the company’s fourth-quarter testing revenue came in ahead of expectations and management issued 2026 testing revenue projections that were higher than consensus estimates. The analy... Full story

Yahoo Finance • 2 months ago

UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue

Veracyte, Inc. (NASDAQ:VCYT) ranks among the best innovative stocks to buy according to Wall Street analysts. On January 12, UBS reaffirmed its Buy rating for Veracyte, Inc. (NASDAQ:VCYT) alongside a price target of $48. Analyst Lu Li reta... Full story

Yahoo Finance • 2 months ago

BD Merges Biosciences & Diagnostics Business With Waters

Becton, Dickinson and Company BDX, popularly known as BD, recently announced that it has completed the previously disclosed spin-off of its Biosciences & Diagnostic business, followed by the merger of the separated entity with Waters Corpo... Full story

Yahoo Finance • 3 months ago

Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)

Veracyte, Inc. (NASDAQ:VCYT) is among the 12 Best Genomics Stocks to Invest In.Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT) The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT... Full story

Yahoo Finance • 3 months ago

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., December 29, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thur... Full story

Yahoo Finance • 3 months ago

3 Medical Instrument Stocks to Counter Industry Woes Using GenAI

Over the past year, the application of generative AI (genAI) in the Medical Instruments industry has moved from experimental to operational, transforming diagnostics, patient monitoring and intervention workflows. Insights from a U.S. Nati... Full story

Yahoo Finance • 5 months ago

Veracyte (VCYT) Turns Profitable, But Significant $27M Loss Challenges Bullish Narratives

Veracyte (VCYT) recently moved into profitability, with its net profit margin turning positive even as a significant, non-recurring loss of $27.0 million affected the latest twelve-month results to September 30, 2025. Over the past five ye... Full story

Yahoo Finance • 5 months ago

After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session was marked by sharp price movements as... Full story

Yahoo Finance • 5 months ago

Veracyte raises 2025 revenue outlook to $510M while accelerating double-digit growth investments

Earnings Call Insights: Veracyte, Inc. (VCYT) Q3 2025 MANAGEMENT VIEW * Marc Stapley, CEO, highlighted "another outstanding quarter" with core testing business revenue up 18% year-over-year after adjusting for Envisia, supported by 26%... Full story

Yahoo Finance • 6 months ago

Do You Believe in the Upside Potential of Veracyte (VCYT)

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets continued their strength in the third quarter, e... Full story

Yahoo Finance • 8 months ago

Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential

Veracyte Inc (NASDAQ:VCYT [https://www.chartmill.com/stock/quote/VCYT]) has been recognized as a possible option for value investors after being selected through a "Decent Value" screening method. This approach looks for stocks with good v... Full story

Yahoo Finance • 8 months ago

Earnings call transcript: Veracyte's Q2 2025 earnings beat expectations, stock falls

Veracyte Inc. reported a significant earnings beat for the second quarter of 2025, with actual earnings per share (EPS) of $0.44 surpassing forecasts of $0.11, marking a 300% surprise. Revenue also exceeded expectations, coming in at $130.... Full story

Yahoo Finance • 8 months ago

Veracyte raises 2025 revenue guidance to $504M as Decipher volumes surge and strategic investments accelerate

Earnings Call Insights: Veracyte, Inc. (VCYT) Q2 2025 MANAGEMENT VIEW * CEO Marc A. Stapley stated that "We delivered 14% revenue growth year-over-year with total revenue of $130 million." He cited testing revenue growth of 14% year-ov... Full story

Yahoo Finance • 9 months ago

Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion

We recently published 10 Shares Explode as Earnings Impress. Veracyte, Inc. (NASDAQ:VCYT) is one of the best-performing stocks on Friday. Veracyte grew its share price by 7.04 percent on Friday to close at $25.25 apiece following announce... Full story

Yahoo Finance • 9 months ago

Cathie Wood's ARK ETF adjusts portfolio, buys ABSCI, sells CRISPR

In the latest trading session, Cathie Wood’s ARK ETFs made several significant transactions as part of their ongoing portfolio adjustments. On Friday, July 25th, 2025, the most substantial trade came from the purchase of 2,248,226 shares o... Full story

Yahoo Finance • 9 months ago

Veracyte Set to Join S&P SmallCap 600

NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners... Full story

Yahoo Finance • 9 months ago

Oversold Conditions For Veracyte (VCYT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 9 months ago

Veracyte Q3 2024 slides: Revenue surges 29%, guidance raised for third time

Introduction & Market Context Veracyte Inc (NASDAQ:VCYT) presented its third quarter 2024 business and financial results on November 6, 2024, showcasing exceptional performance with 29% year-over-year revenue growth. The cancer diagnosti... Full story